EP0446047B1 - Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren - Google Patents

Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren Download PDF

Info

Publication number
EP0446047B1
EP0446047B1 EP91301895A EP91301895A EP0446047B1 EP 0446047 B1 EP0446047 B1 EP 0446047B1 EP 91301895 A EP91301895 A EP 91301895A EP 91301895 A EP91301895 A EP 91301895A EP 0446047 B1 EP0446047 B1 EP 0446047B1
Authority
EP
European Patent Office
Prior art keywords
group
composition
formula
elastase
benzisothiazolinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP91301895A
Other languages
English (en)
French (fr)
Other versions
EP0446047A1 (de
Inventor
Ladislas Robert
Elemer Moczar
William Georges Hornebeck
Christiane Marie-Pierre Kerneur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Unilever NV
Original Assignee
Unilever PLC
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Unilever NV filed Critical Unilever PLC
Publication of EP0446047A1 publication Critical patent/EP0446047A1/de
Application granted granted Critical
Publication of EP0446047B1 publication Critical patent/EP0446047B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention relates to benzisothiazolinone-1-dioxide derivatives that can be used as elastase inhibitors, and to compositions containing such inhibitors.
  • elastin is an elastic fibrous protein that occurs in the connective tissues of vertebrates. It is found in the walls of the blood vessels, the skin, lungs, cartilage, ligaments and other tissues. Elastin is the most durable protein in the body, but it suffers a particularly rapid degradation in all the elastin-rich tissues. Such as the vascular walls and the skin, in certain pathological conditions, as well as during the ageing process in general.
  • Elastin can be attacked only by certain proteases, called elastases or elastase-type proteases. These enzymes include pancreatic elastase and cell elastases, examples of the latter being leucocytic and platelet elastases, as well as the elastases found in macrophages, fibroblasts and the cells of the smooth muscles in the arteries. These enzymes can degrade the elastin in the tissues and organs mentioned above and so contribute to the development of disorders such as arteriosclerosis, emphysema, arthritis and diabetes, as well as to the ageing of the connective tissues in the body.
  • elastases The activity of elastases is controlled and regulated by natural inhibitors present in the plasma (e.g. ⁇ -1-antitrypsin and ⁇ -2-macroglobulin) and in secretions from tissues (e.g. the bronchial secretion) [see e.g. W. Hornebeck et al., "Control of elastic tissue destruction by elastase inhibitors", in Deyl and Adam (eds.), Connective Tissue Research: Chemistry, Biology and Physiology, pp. 233-246, A.R. Liss Inc., New York, 1981].
  • natural inhibitors present in the plasma e.g. ⁇ -1-antitrypsin and ⁇ -2-macroglobulin
  • secretions from tissues e.g. the bronchial secretion
  • elastases are useful or even indispensable for the body, for example when they digest the bacteria that have been destroyed by the phagocytic action of macrophages. It is therefore important to possess elastase inhibitors that act selectively in the elastic fibres whose integrity is indispensable for the proper functioning of the body.
  • EP-A 0 126.009 describes some peptide derivatives that can be used as elastase inhibitors and are specific for elastic fibres. These derivatives are lipopeptides with a hydrophobic acyl group and a special peptide chain. However, these lipopeptides, which are consequently bifunctional, have the major disadvantage of containing a peptide moiety, which is susceptible to hydrolysis by other proteinases.
  • the aim of the present invention is therefore to incorporate into pharmaceutical or cosmetic compositions elastase inhibitors in the form of bifunctional benzisothiazolinone-1-dioxide derivatives with a) a hydrophobic chain that has an affinity for elastin and b) a moiety that is not a peptide group (so that it is more resistant to enzymatic hydrolysis) and which can also acrylate the active serine in the elastase.
  • the present invention therefore provides a composition
  • a composition comprising (i) an elastase inhibitor which is at least one benzisothioazolinone-1-dioxide derivative having the formula: where R 1 is a hydrogen atom or a C 1 -C 5 alkyl or alkoxy group, and
  • a benzisothiazolinone-1-dioxide derivative of formula (I) above, which is the active ingredient of a composition as above, has two functional groups, namely a "lipid arm” (R 2 or part of R 2 ), which has a high affinity for the elastic fibres in question, and the benzisothiazolinone-1-dioxide moiety, which can react with elastase in order to inhibit it.
  • the benzisothiazolinone-1-dioxide derivatives of the present invention can accumulate on the elastic fibres to be protected and therefore act exclusively or almost exclusively on the elastase located near these fibres. In view of this mode of action, it is possible to make the substance act specifically at the site of the target fibres to be protected, which ensures a more efficient inhibition of elastase.
  • the compounds according to the invention are therefore more efficient and more economical bifunctional inhibitors than the known synthetic inhibitors, which lack the functional group that has a special affinity for the elastic fibres present in the tissues to be protected.
  • the affinity of the derivative for elastin and for the hydrophobic site on the elastase does not become detectable until the number of carbon atoms reaches nine, improving as the number reaches eleven and peaking when this number is 16.
  • a monovalent C 11 -C 20 straight-chain or branched alkyl group can carry at least one substituent in the form of an OH or COOH group.
  • alkyl groups include the nonyl, undecyl, tridecyl, pentadecyl, heptadecyl and nonadecyl groups, while COOH-(CH 2 ) 8 - is an example of the substituted alkyl groups.
  • An aromatic nucleus may comprise one or more benzene rings, examples being the groups obtained from benzene, anthracene, naphthalene, biphenyl, terphenyl, triphenylbenzene, indene, diphenylene, fluorene and phenanthrene.
  • a divalent group R 5 may in particular be a group theoretically obtainable by removing a hydrogen atom from each of two terminal carbons in a straight-chain or branched C 8 -C 20 alkane, alkene or polyalkene, as exemplified by the -(CH 2 ) 8 - group.
  • R 1 can be a hydrogen atom or a substituent chosen from amongst C 1 -C 5 alkyl or alkoxy groups. When R 1 is a substituent, it is desirably chosen such as to promote the hydrolytic opening of the heterocyclic ring. However, R 1 is generally a hydrogen atom.
  • R 2 is the functional group that confers an affinity for the elastic fibres on the compound of the invention, owing to its lipophilic nature.
  • R 2 is a long-chain alkyl or alkenyl group whose long hydrocarbon chain confers a strongly lipophilic nature on the compound according to the invention. This facilitates its penetration into the skin and makes it suitable for cosmetic use.
  • R 2 is a group with the formula: where R 3 and R 4 are as defined before; R 3 is preferably a divalent group obtained from an alkane is a benzene ring R 4 is a C 1 -C 4 alkoxy group or a hydroxyl group, and n is 1 or 2.
  • R 2 groups are exemplified by the 3,4-dimethoxycinnamoyl, cinnamoyl, dihydrocinnamoyl and p-methoxyphenylbutyryl radical.
  • the compound according to the invention is again lipophilic, this time because it comprises an aromatic nucleus.
  • R 2 has the following formula:
  • this R 5 group confers on the compound both a lipophilic character and an affinity for the elastic fibres in question, while the presence of two benzisothiazolinone-1-dioxide rings increases the inhibitory activity.
  • the benzisothiazolinone-1-dioxide derivatives of this invention can be prepared by conventional methods in which the starting materials are an acid chloride and an alkali metal derivative of the corresponding benzisothiazolinone-1-dioxide.
  • the benzisothiazolinone-1-dioxide derivative with formula I in which R 1 is as defined above and R 2 represents the group with formula (III) where R 1 and R 5 are as defined before can be prepared by reacting an alkali metal derivative of a benzisothiazolinone-1-dioxide having formula (IV) with an acid chloride represented by: ClCO-R 5 -COOH (VI) where R 5 is as defined before, the alkali metal being preferably sodium, but potassium can also be used.
  • the reaction between the alkali metal derivative and the acid chloride can be carried out in both cases by refluxing the alkali metal derivative of the benzisothiazolinone-1-dioxide (IV) with the acid chloride (V) or (VI) in a suitable solvent such as tetrahydrofuran, with stirring.
  • a suitable solvent such as tetrahydrofuran
  • This invention also embraces methods of treatment comprising administration of compositions of this invention as specified above, especially cosmetic treatment by topical application.
  • compositions of this invention may be solutions, suspensions, emulsions, ointments, creams, powders, lotions or gels, with non-toxic carriers or vehicles and possibly also additives and excipients.
  • the compounds of the invention can thus be incorporated in conventional excipients such as polyethylene glycols, waxes, fats, stearic substances, talc, alcohols, vegetable oils (e.g. sweet or expressed almond oil), mineral oils, wetting agents, thickeners, preservatives, perfumes and colorants.
  • excipients such as polyethylene glycols, waxes, fats, stearic substances, talc, alcohols, vegetable oils (e.g. sweet or expressed almond oil), mineral oils, wetting agents, thickeners, preservatives, perfumes and colorants.
  • compositions are intended for oral, parenteral, and - most often - local or topical administration.
  • compositions can be used to treat or prevent any undesirable biological or pathological change caused by elastase, such as:
  • the compounds of the invention can also be used as cosmetics intended to counteract the undesirable effects of elastase on the skin, such as ageing.
  • These cosmetics are essentially intended for application to the skin and can be e.g. solutions, emulsions, creams, ointments, powders, lotions, gels, soaps, milks, face packs, aerosols or bath oils.
  • emulsions it is best to use the water-in-oil type, containing the compound of the invention solubilized in the oil phase.
  • These compositions can be prepared by the conventional methods, using the carriers, excipients and additives normally incorporated in such compositions.
  • the concentration of the new derivative (I) in the composition is chosen according to its activity and the effect required.
  • the composition can contain the compound of the invention in a concentration of 0.1 to 5 wt-%.
  • compositions according to the invention that are intended for local application may also contain penetration enhancers or penetration potentiators, which can raise the beneficial effect of the elastase inhibitor by improving its diffusion through the epidermis until it reaches its site of action in the stratum corneum.
  • penetration enhancers can act in different ways. For example, they can improve the distribution of the elastase inhibitor on the surface of the skin. Alternatively, they can improve its distribution in the skin after local application, thus promoting the migration of the elastase inhibitor within the stratum corneum. The penetration enhancers may also raise the efficiency of the elastase inhibitor by other mechanisms.
  • compositions according to the invention can optionally comprise up to 30 wt-% and preferably 0.1-25 wt-% of a penetration enhancer, examples of which are listed below.
  • the preferred esters are those in which R is a straight-chain or branched alkyl group with 1-14 and preferably 1-6 carbon atoms.
  • Other preferred examples of pyroglutamic acid esters are those in which R represents the group: where the symbols T' and T" stand for the group: [(CH 3 ) u .(CH 2 OH) v .(CH 2 ) w .(CH 3 CH 2 ) x .(CHOH) y.
  • (CH CH) z ] - and which comprise saturated or unsaturated straight-chain or branched C 1 -C 22 aliphatic groups such as the alkyl groups: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, n-valeryl, isovaleryl, n-caproyl, n-heptyl, n-caprylyl, n-capryl, lauryl, myristyl, palmityl, stearyl and arachidyl group, and the C 10 -C 22 alkenyl groups: linoleyl, linolenyl, ⁇ -linolenyl, arachidonyl and columbinyl group.
  • C 1 -C 22 aliphatic groups such as the alkyl groups: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, n-valeryl, isovale
  • hydroxyalkyl radicals with 1-22 carbon atoms such as the hydroxymethyl, 2-hydroxyethyl, 2-hydroxy-n-propyl, 3-hydroxy-n-propyl, 2-hydroxy-n-butyl, 3-hydroxy-n-butyl, 4-hydroxyl-n-butyl, 5-hydroxy-n-valeryl, 6-hydroxy-n-caproyl, 2,3-dihydroxy-n-propyl, 2,3-dihydroxy-n-butyl and 12-hydroxystearyl group.
  • pyroglutamic acid esters that are particularly suitable for use as penetration enhancers are as follows:
  • penetration enhancers are as follows:
  • Example 1 The method described in Example 1 was used to prepare various compounds with formula I, in which the groups denoted by R 1 and R 2 are shown in Table 1.
  • the acid chloride used here was myristoyl chloride in Example 2, palmitoyl chloride in Example 3, stearoyl chloride in Example 4, decanoyl chloride in Example 5 and undecenoyl chloride in Example 6.
  • the melting points of the compounds obtained are given in Table 1.
  • Example 7 The method described in Example 7 was used to prepare various compounds with formula I, in which the groups denoted by R 1 and R 2 are shown in Table 1.
  • the acid chloride used here was cinnamoyl chloride in Example 8, dihydrocinnamoyl chloride in Example 9, and p-methoxyphenylbutyryl chloride in Example 10.
  • the melting points of the compounds obtained are given in Table 1.
  • the inhibition test was carried out by using succinyl-trialanine p-nitroanilide as a synthetic substrate.
  • Human leucocytic elastase used at concentration of 1 ⁇ g/ml, was first pre-incubated for 15 min with the compounds of the invention, used at a concentration of 0.5, 5, 10, 25 and 50 ⁇ g/ml. These compounds were added in the form of a solution in acetone, the final acetone concentration of the reaction mixture being 1%.
  • the degree of hydrolysis of the substrate was determined by measuring the amount of p-nitroaniline released, using a Philips PO 8700 spectrophotometer at 410 nm.
  • the 50% inhibitory concentration (IC 50 ) in mole/litre was then determined by a graphical method, using the inhibition values obtained with the different concentrations of the substrate and the inhibitor.
  • Table 1 shows the IC 50 values obtained for the compounds of the invention prepared in Examples 1-5. It can thus be seen that the inhibitory action of these compounds increases with the number of carbon atoms in the R 2 group on going from C 9 to C 17 .
  • the degree of the hydrolysis of elastin was calculated in all three cases after incubation with elastase for 7 h at 37°C by determining the radioactivity in the solubilized peptides derived from the elastin.
  • the aim of the first series was to determine the direct ability of 2-lauroylbenzisothiazolinone-1-dioxide to inhibit the activity of human leucocytic elastase.
  • the results show that, when used in a concentration of 45 ⁇ g/ml, 2-lauroylbenzisothiazolinone-1-dioxide inhibits the elastin-cleaving activity of human leucocytic elastase by 80%, the value of IC 50 being 7.5 x 10 -5 M.
  • the second and third series of investigations showed that the compound of the invention also protects the insoluble elastic fibres from the action of human leucocytic elastase with a maximum inhibition of 50% when used in a concentration of 50-100 ⁇ g/ml, the IC 50 value being 1.3-2.9 x 10 -4 M.
  • Frozen biopsy specimens of rabbit skin having a thickness of 6 ⁇ were treated either with human leucocytic elastase in a concentration of 15 ⁇ g/ml or with a mixture of this and 2-lauroylbenzisothiazolinone-1-dioxide, prepared in Example 1 and used in a concentration of 350 ⁇ g/ml.
  • the segments of rabbit skin were incubated for 1.5 h at 37°C. In the control experiment, they were incubated only with the buffer (100-mM tris-HCl, 0.1% of Brij 35, pH 8) under the same conditions.
  • V occupied by the cutaneous elastic fibres was 6.25 ⁇ 0.5%. After treatment with human leucocytic elastase, this value was only 4.1 ⁇ 0.8%. When the elastase was first incubated with 2-lauroylbenzisothiazolinone-1-dioxide, however, the value of V was 6.00 ⁇ 1%, which indicates a virtually complete (96%) protection from the action of elastase.
  • plasmin the activity of a) pig pancreatic elastase, b) trypsin, c) thrombin and d) plasmin was determined in the presence of these inhibitors and of the synthetic substrates: a) succinyltrialanine p-nitroanilide, b) N-benzoyl-DL-arginine p-nitroanilide, c) N-p-tosyl-gly-pro-arg p-nitroanilide and d) N-p-tosyl-gly-pro-lys p-nitroanilide, respectively.
  • Each enzyme was first incubated for 15 min with 0-50 ⁇ g/ml of compound B or P mentioned above, which had been dissolved in acetone as in the test with human leucocytic elastase, the final concentration of this solvent in the reaction mixture being 1%.
  • the appropriate substrate was then added to each enzyme, and its hydrolysis was monitored with a Philips 8700 spectro-photometer at 410 nm by measuring the amount of p-nitroaniline appearing in the medium.
  • E/IC 50 the concentration of the enzyme in the reaction mixture (also expressed in mole/l ). The higher the value of this quotient, the stronger the inhibitory activity, and therefore the lower the number of moles of the inhibitor that are needed to obtain a 50% inhibition for the same number of moles of the enzyme.
  • 2-Palmitoyl-2-benzisothiazolinone-1-dioxide inhibits human leucocytic elastase, pig pancreatic elastase and trypsin 20-40 times as strongly as it inhibits thrombin. This indicates that the compound according to the invention, i.e. 2-palmitoyl-benzisothiazolinone-1-dioxide, is much more efficient than 2-butyrylbenzisothiazolinone-1-dioxide, in which the hydrocarbon chain contains fewer than nine carbon atoms.
  • Examples 16-21 illustrate some cosmetic compositions containing elastase inhibitors according to the present invention.
  • This Example illustrates a gel for the treatment of hair, this product containing the compound mentioned in Example 2, i.e. 2-myristoylbenzisothiazolinone-1-dioxide, and having the following composition.
  • This Example illustrates a face pack containing the inhibitor used in Example 4, i.e. 2-stearoylbenzisothiazolinone-1-dioxide, and having the following composition, the product being prepared by mixing the ingredients together.
  • This Example illustrates a lotion suitable for the treatment of nails, containing the inhibitor used in Example 6, i.e. 2-undecenoylbenzisothiazolinone-1-dioxide, and having the following composition, the lotion (which had a pH of 4.4) being prepared by homogenizing the mixture of its ingredients.
  • This Example illustrates a skin cream formed by a water-in-oil emulsion and containing the inhibitor from Example 1, i.e. 2-lauroylbenzisothiazolinone-1-dioxide in its continuous oil phase, the composition of the cream being as follows. Amount, wt-% Silicones 24.00 Sodium chloride 2.00 Inhibitor from Example 1 3.00 Lactic acid 5.00 Humectants 5.00 Bleaching agent 0.15 Preservatives 0.05 Oil of evening primrose 3.00 Sunscreens 4.00 Bactericides 0.30 Water 53.50 100.00 ⁇
  • This skin cream which had a pH of 4, was prepared by mixing the silicones, the bleaching agent and the preservatives together, adding a mixture of the other ingredients in small portions, and homogenizing the product.
  • This Example illustrates a water-in-oil type cream, which contained sunscreens in its continuous oil phase, together with the inhibitor from Example 7, i.e. 2-(3,4-dimethyoxycinnamoyl)-benzisothiazolinone-1-dioxide.
  • This cream had the following composition. Amount, wt-% Silicones 24.00 Humectants 10.00 Bleaching agent 0.15 Preservatives 0.05 Oil of evening primrose 3.00 Sunscreens 4.00 Bactericides 0.30 Inhibitor from Example 7 1.00 Ammonium hydroxide 2.00 Ammonium chloride 2.00 Lactic acid 5.00 Water 48.50 100.00 ⁇
  • This Example illustrates a water-in-oil type cream that contained sunscreens in its continuous oil phase, together with the inhibitor with formula (VIIa) from Example 11, i.e. 1,10-decanedioyl-bis-benzisothiazolin-3-oxo-1,1-dioxide), the cream having the following composition.

Claims (12)

  1. Eine kosmetisch oder pharmazeutisch geeignete Zusammensetzung, enthaltend
    (i) einen Elastase-Inhibitor, welcher zumindest ein Benzisothiazolinon-1-dioxid-Derivat mit der nachstehenden Formel I ist
    Figure imgb0035
     worin
    R1   ein Wasserstoffatom oder eine C1-5-Alkyl- oder Alkoxygruppe ist, und
    R2   eine einwertige C11-20-Alkyl- oder Alkenylgruppe ist, gegebenenfalls substituiert mit OH- oder COOH-Gruppe, oder Dec-9-enyl bedeutet,
    R2   eine Gruppe der Formel II ist
    Figure imgb0036
     worin
    R3   eine zweiwertige geradkettige oder verzweigtkettige, gesättigte oder ethylenisch ungesättigte aliphatische C2-6-Gruppe ist,
    Figure imgb0037
       ein aromatischer Nucleus ist,
    R4   OH, eine C1-4-Alkyl- oder eine C1-4-Alkoxygruppe ist,
    n   den Wert Null aufweist oder eine ganze Zahl im Bereich von 1 bis 5 bedeutet, und, falls n > 1 ist, können die R4-Gruppen verschieden sein, oder weiter ist
    R2   eine Gruppe mit der Formel III
    Figure imgb0038
    worin
    R1   die gleiche Bedeutung wie oben besitzt, und
    R5   eine zweiwertige geradkettige oder verzweigtkettige, gesättigte oder ethylenisch ungesättigte aliphatische C8-20-Gruppe ist,
    und (ii) einen pharmazeutisch oder kosmetisch annehmbaren Träger oder Vehikel.
  2. Zusammensetzung nach Anspruch 1, worin R2 eine C11-20-Alkylgruppe ist.
  3. Zusammensetzung nach Anspruch 2, worin R1 ein Wasserstoffatom ist.
  4. Zusammensetzung nach Anspruch 1, worin R1 ein Wasserstoffatom und R2 eine mit COOH substituierte Alkylgruppe, oder eine Alkenylgruppe, ist.
  5. Zusammensetzung nach Anspruch 1, worin R1 ein Wasserstoffatom ist und R2 aus Nonyl-, Undecyl-, Tridecyl-, Pentadecyl-, Heptadecyl-, Carboxyoctyl- und Dec-9-enyl-Gruppen ausgewählt ist.
  6. Zusammensetzung nach Anspruch 1, worin R1 ein Wasserstoffatom ist und R2 eine Gruppe mit der Formel
    Figure imgb0039
     bedeutet, worin R3 eine gesättigte oder olefinisch ungesättigte zweiwertige aliphatische C2-6-Gruppe bedeutet, R4 eine Hydroxylgruppe oder eine C1-4-Alkoxygruppe ist und n = 1 oder 2.
  7. Zusammensetzung nach Anspruch 6, worin R2 eine 3,4-Dimethoxycinnamoyl-, Cinnamoyl-, Dihydrocinnamoyl- oder p-Methoxyphenylbutyrylgruppe ist.
  8. Zusammensetzung nach Anspruch 1, worin R1 ein Wasserstoffatom bedeutet und R2 eine Gruppe mit der Formel III
    Figure imgb0040
     ist, worin R1 Wasserstoff und R5 eine zweiwertige gesättigte aliphatische Gruppe bedeutet.
  9. Zusammensetzung nach einem der vorstehenden Ansprüche, welche 0,1 bis 5 Gewichtsprozent der Verbindung der Formel I enthält.
  10. Ein Verfahren zur kosmetischen Behandlung der menschlichen Haut, umfassend das örtliche Aufbringen einer Zusammensetzung gemäß einem der Ansprüche 1 bis 9 darauf.
  11. Die Verwendung eines Benzisothiazolinon-1-dioxid-Derivats gemäß der Definition in irgendeinem der Ansprüche 1 bist 7 in einer kosmetischen Zusammensetzung.
  12. Die Verwendung eines Benzisothiazolinon-1-dioxid-Derivats gemäß der Definition in irgendeinem der Ansprüche 1 bis 7 für die Herstellung einer pharmazeutischen Zusammensetzung für die Inhibierung von Elastase.
EP91301895A 1990-03-08 1991-03-07 Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren Expired - Lifetime EP0446047B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9002951 1990-03-08
FR9002951A FR2659327A1 (fr) 1990-03-08 1990-03-08 Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.

Publications (2)

Publication Number Publication Date
EP0446047A1 EP0446047A1 (de) 1991-09-11
EP0446047B1 true EP0446047B1 (de) 1997-06-11

Family

ID=9394523

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91301895A Expired - Lifetime EP0446047B1 (de) 1990-03-08 1991-03-07 Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren

Country Status (16)

Country Link
US (2) US5338747A (de)
EP (1) EP0446047B1 (de)
JP (1) JPH04234863A (de)
KR (1) KR960014782B1 (de)
AT (1) ATE154347T1 (de)
AU (1) AU636013B2 (de)
BR (1) BR9100938A (de)
CA (1) CA2037665A1 (de)
DE (1) DE69126460T2 (de)
ES (1) ES2102994T3 (de)
FR (1) FR2659327A1 (de)
ID (1) ID820B (de)
IN (1) IN172035B (de)
MY (1) MY106067A (de)
TW (1) TW200472B (de)
ZA (1) ZA911728B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906181B (zh) * 2003-11-14 2011-05-11 3M创新有限公司 含有n-磺酰基氨基羰基的化合物

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512589A (en) * 1990-11-01 1996-04-30 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5250696A (en) * 1990-11-01 1993-10-05 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylate
US5306818A (en) * 1990-11-01 1994-04-26 Sterling Winthrop Inc. Tetrahydro 2-saccharinylmerthyl aryl carboxylates
TW226016B (de) * 1991-12-30 1994-07-01 Sterling Winthrop Inc
AU653279B2 (en) * 1991-12-30 1994-09-22 Sanofi Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US6375948B1 (en) * 1999-07-12 2002-04-23 Kao Corporation Treating method for suppressing hair growth
GB0129987D0 (en) * 2001-12-14 2002-02-06 Zylepsis Ltd Skin compositions
US7943388B2 (en) 2003-11-14 2011-05-17 3M Innovative Properties Company Acoustic sensors and methods
US7361767B2 (en) 2003-11-14 2008-04-22 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
KR101130956B1 (ko) * 2003-11-14 2012-03-30 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Ｎ-술포닐아미노카르보닐 함유 화합물
WO2005066121A2 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Multifunctional amine capture agents
US7342082B2 (en) 2004-12-17 2008-03-11 3M Innovative Properties Company Soluble polymers as amine capture agents and methods
US7402678B2 (en) 2004-12-17 2008-07-22 3M Innovative Properties Company Multifunctional amine capture agents
US7544756B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544755B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544754B2 (en) * 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US8034448B2 (en) * 2008-08-19 2011-10-11 Los Alamos National Security, Llc Fibrous composites comprising carbon nanotubes and silica
ES2534193T3 (es) 2009-12-01 2015-04-20 Lubrizol Advanced Materials, Inc. Polímeros hidrolíticamente estables para múltiples fines
CA3041033A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
JP7065081B2 (ja) 2016-09-12 2022-05-11 インテグラル ヘルス， インコーポレイテッド Ｇｐｒ１２０モジュレーターとして有用な二環式化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195023A (en) * 1975-08-20 1980-03-25 Merck & Co., Inc. 2-(2-Furoyl)1,2-benzisothiazole-3-one, 2-(2-furoyl) saccharin, and 2-(2-thenoyl) saccharin
US4276298A (en) * 1978-03-24 1981-06-30 Merck & Co., Inc. 2-Aryl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
FR2546164B1 (fr) * 1983-05-16 1987-07-17 Centre Nat Rech Scient Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906181B (zh) * 2003-11-14 2011-05-11 3M创新有限公司 含有n-磺酰基氨基羰基的化合物

Also Published As

Publication number Publication date
TW200472B (de) 1993-02-21
US5338747A (en) 1994-08-16
BR9100938A (pt) 1991-11-05
ATE154347T1 (de) 1997-06-15
DE69126460D1 (de) 1997-07-17
ZA911728B (en) 1992-11-25
FR2659327A1 (fr) 1991-09-13
MY106067A (en) 1995-03-31
IN172035B (de) 1993-03-20
EP0446047A1 (de) 1991-09-11
KR960014782B1 (en) 1996-10-19
DE69126460T2 (de) 1997-12-04
AU636013B2 (en) 1993-04-08
KR910016330A (ko) 1991-11-05
AU7263591A (en) 1991-09-12
CA2037665A1 (en) 1991-09-09
JPH04234863A (ja) 1992-08-24
ID820B (id) 1996-07-22
US5411978A (en) 1995-05-02
ES2102994T3 (es) 1997-08-16

Similar Documents

Publication Publication Date Title
EP0446047B1 (de) Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren
US7838020B2 (en) Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor
US7998933B2 (en) Process for treating the skin comprising applying to the skin at least one composition comprising at least one N-aminoacylamide
EP0630228B1 (de) Mittel zur regulierung vom hautfettigkeitsgrad
US4906617A (en) Pharmaceutical compositions containing saturated aromatic peroxides
EP0088542B1 (de) Hautbehandlungsmittel
JPH07316034A (ja) ４位、４位および５位、または４位および６位がモノ‐もしくはジ‐置換されたレゾルシノール誘導体を、色素脱失作用を有する化粧品組成物もしくは皮膚薬剤組成物に使用する方法
US5641494A (en) Agent for regulating the greasiness of the skin
US7041658B2 (en) Method of inhibiting hair growth
FR2818903B1 (fr) Composition transparente de traitement cosmetique, de type emulsion eau-dans-huile, et procede de traitement cosmetique des matieres keratiniques
US6004543A (en) L-2-oxothiazolidine-4-carboxylic acid derivatives and use thereof for skincare
EP0606197A1 (de) Derivate von aromatischen benzoaten als inhibitoren esteraseproduzierender mikroorganismen.
EP0304665B1 (de) 2,4,6-Triaminopyrimidin N-3-oxid-Harnstoff-Derivate, deren Herstellung und deren kosmetische und dermopharmazeutische Verwendung
US20040191203A1 (en) Cosmetic or dermatological composition comprising n-acylaminoamide derivatives
JP4002635B2 (ja) 細胞間接着抑制剤
JP2552298B2 (ja) 美肌化粧料
JP2001335472A (ja) チロシナーゼ活性阻害剤及び化粧料
EP1394161B1 (de) L-ascorbinsäure-2-o-maleinsäure-a-tocopheroldiester-1-propanol addukt und verfahren zu dessen herstellung
JP2998846B2 (ja) 美白化粧料
US6022532A (en) Agent for regulating the greasiness of the skin
CA2290702C (en) Topical compositions and methods for reducing ageing processes of skin and treating pathological lesions of skin
JPH03101676A (ja) ２―エトキシメチル―５―ヒドロキシ―γ―ピロン及び同化合物を有効成分とするメラニン生成抑制外用剤
JP2002212068A (ja) 線溶系プロテアーゼ阻害剤
JPH11124309A (ja) 化粧料

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL SE

17P Request for examination filed

Effective date: 19911218

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNILEVER N.V.

Owner name: UNILEVER PLC

17Q First examination report despatched

Effective date: 19940609

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19970611

Ref country code: LI

Effective date: 19970611

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19970611

Ref country code: DK

Effective date: 19970611

Ref country code: CH

Effective date: 19970611

Ref country code: BE

Effective date: 19970611

Ref country code: AT

Effective date: 19970611

REF Corresponds to:

Ref document number: 154347

Country of ref document: AT

Date of ref document: 19970615

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69126460

Country of ref document: DE

Date of ref document: 19970717

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2102994

Country of ref document: ES

Kind code of ref document: T3

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19970911

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19980209

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19980225

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980309

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19980307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991130

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000101

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20000601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050307